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Introduction
More than 3.5 million Americans are living with breast cancer, of whom 41,070 (40,610 women and 460 men) died from the disease in 2017 (1) . Despite substantial improvements in the treatment and prognosis of early-stage breast cancer, little is known about changes in survival and other outcomes of metastatic breast cancer (MBC) patients (2,3). MBC can be found at initial diagnosis (de novo Stage IV disease) or as a distant recurrence of the primary tumor.
Electronic medical records (EMR) contain large amounts of data collected during routine medical care delivery and have the potential to generate practice-based evidence. However, it has been challenging to make use of this abundance of data in part because of difficulties in identifying which breast cancer patients have had metastatic recurrence (4). Although de novo (5, 6) . SEER registries are funded to record only the first few months of treatment, and continuous follow-up by any registry to assess for metastatic recurrence would be costly. Thus, there is a profound gap in our knowledge about treatment of MBC and how patients die of this disease.
Manual case detection to identify metastatic cohorts is prohibitively laborious. An informatics approach to bridge the knowledge gap would be to identify recurrent MBC patients retrospectively from administrative healthcare claims and EMRs, which contain large amounts of data collected during routine medical care delivery and have the potential to generate much needed real-world evidence. Prior studies have developed rule-based approaches that use structured data such as qualifying diagnoses, procedures and drug codes (7) (8) (9) (10) (11) . While such approaches are simple to replicate in a new dataset, their reliability is challenged by coding bias and differential coding practices. In addition, these approaches can suffer from low sensitivity (40%-60%), despite reasonable specificity (70%-90%) (8) (9) (10) . A promising alternative is emerging systems that analyze unstructured clinical text in EMR and have shown higher sensitivity and specificity (12, 13) . However, their limitations include a high cost of initial development, difficulty in adapting to new systems, and most significantly, the requirement for a prohibitively large amount of manually annotated training data.
We sought to develop a semi-supervised machine learning framework for automating MBC case detection with the potential to support population-level surveillance research across California and nationally. Semi-supervised machine learning comprises a class of supervised learning techniques that make use of unlabeled data to train machine learning models. It falls between unsupervised learning (no labeled training data) and supervised learning (completely labeled training data). It typically consists of pairing a small amount of labeled data with a large amount of unlabeled data --or in the case of the method distant supervision, a distinct data source that can be used to label training examples automatically for supervised learning, in the absence of human-labeled training data. By leveraging the complementary patient data contained in the EMR and in the California Cancer Registry, our methodological innovation extends the distant supervision paradigm described by Mintz et al. to the problem of MBC case detection (14) (15) (16) .
Methods

Data Source
The Oncoshare breast cancer research database comprises a three-way data linkage at the patient level. It is an integration of retrospective EMRs of Stanford Health Care (SHC) and multiple sites of the Palo Alto Medical Foundation (PAMF) in Northern California, both linked to data from California Cancer Registry, a SEER registry (17, 18) . Only SHC patients were included in this study. Human Subjects approval for all research reported here was obtained from the Institutional Review Boards of Stanford University and the State of California.
The structured EMR fields in Oncoshare's clinical database include each patient's diagnoses, procedures and drug orders. The unstructured EMR fields include free-text clinician notes such as medical and social histories, impressions, and visit summaries. The CCR contains detailed demographic information such as patient age, race/ethnicity, zip code and neighborhood characteristics, insurance and marital status, tumor characteristics at initial breast cancer diagnosis, and continually updated survival data which SEER obtains through linkage to the Social Security Death Master file and other national databases (17, 18) .
For this study, we focused on 11,459 breast cancer patients treated at SHC from 2000-2014.
Descriptive information on the study population appears in Supplementary Tables S1 and S2.   Supplemental Table S1 . Length of follow-up in days by survival status and tumor stage at initial diagnosis in Stanford Health Care patients. 
Distant Supervision of MBC Classification
Our distant supervision framework exploits the Oncoshare EMR-CCR linkage. In the absence of a large number of manually annotated cases, we used one data source from the linked data, EMR, to infer a class label for metastatic recurrence. These class labels were then used to supervise the learning of a classification model using input variables from the other data source, CCR. Our methodological innovation is to extend the distant supervision paradigm described by Mintz et al., which has been applied for over a decade in the development of general domain natural language processing (NLP) and information extraction tools, to clinical case detection (15) .
Step 1: Processing EMR Clinical Notes and Assigning Distant Labels
In
Step 1, we used NLP-derived features to label patients that were likely to have experienced a metastatic recurrence, based on free-text patient notes in the EMR. Specifically, we adapted an open-source clinical text analysis tool, CLEVER (CL-inical EV-ent R-ecognizer), which has been validated for EMR-based information extraction tasks in prior work, to extract metastatic disease information (19) . This decision was based on the efficiency of CLEVER's tagger, which facilitates the review of intermediate system output by subject matter experts and their inclusion in the development of custom clinical NLP extractors. CLEVER's source code, base terminology, and all customized components that were developed as part of this work are distributed publicly with a MIT software license on Github Although mature clinical NLP systems exist, they can be difficult to install and must be adapted to new sources of data. Simple taggers leveraging resources such as the National Library of Medicine's Unified Medical Language System (UMLS) and SPECIALIST Lexicon tools have been shown to rival their performance and are easier to install (20) . As illustrated in Supplementary Figure S4 , CLEVER makes one modification to these types of general UMLS based taggers such as Noble Coder or MetaMap (21, 22) in that we pre-trained word-and phrase-embedding models on clinical text to expand terminologies that are "seeded" by UMLS terms. Using language-embedding models to identify new terms that were statistically similar to the high quality UMLS seed terms, we bootstrapped the development of an enhanced terminology using an iterative and incremental development process that included two informaticists and a subject matter expert to assist in the review of candidate terms.
After our terminology for MBC information extraction was complete, we used CLEVER to annotate the corpus and extract mentions of different metastatic disease concepts that could be used to infer the presence or absence of a metastatic recurrence. We also examined their immediate contexts to determine if the target term was negated, hypothetical or an attribute of a family member and not the patient (Supplementary Figure 5) . Custom classes that we developed for metastatic recurrence detection are shown in Table 2 . The CLEVER rule that we developed to assign a case label to each patient was based on the positive present mention of a term from at least one of four custom word classes: "METSBONE", "METSBRAIN", "METSLIVER", "METSLUNG". These four word classes were constructed in a data-driven way from the most common sites of metastasis among our patients. In contrast to less specific word classes such as "DRECUR", which contains words and phrases that indicate a non-specific distant recurrence event, these four work classes include terms that indicate both metastatic disease and a location distant to the breast.
Step 2: Recurrent MBC Classification
In
Step 2, we used the distant labels from Step 1 to train a metastatic recurrence classification model, integrating features from the CCR data. Structured fields used as input features of classification models included age, race, ethnicity, marital status, socioeconomic status, insurance type, comorbidity, year of initial breast cancer diagnosis, cancer stage, tumor grade, tumor histology, and tumor receptor status (e.g., expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2/neu)).
Missing data in any of the structured features above were coded as a separate category. There were 427 patient-level features that were output from clinical text processing and were used as input features for patient classification. We included the total number of terms mentioned in each of the customized word classes and their frequency as positive or negative concepts, in each specific note type and across all note types in the EMR. The NLP-derived features that were used to infer the distant label were excluded from this metastatic recurrence classification model, because they would result in "learning back" our inference process.
We trained a logistic regression model with L2 regularization using glmnet package in R (23).
Compared to regular logistic regression, L2 regularization smoothly shrinks regression coefficients based on regularization parameter, lambda, while retaining all input features in the model (24) . Such regularization can help reduce prediction error in our case because many of our input features are likely to be correlated. The probability cutoff of the classifier was chosen to optimize the F1 score. Finally, we tested our classifier on a physician-labeled set of 146 patients (72 cases who had metastatic recurrence and 74 controls who did not have metastatic recurrence) and measured model performance using sensitivity, specificity, positive predictive value (PPV or precision), negative predictive value (NPV), and overall accuracy. In order to quantify the contribution of NLP-derived features in our classification model, we also trained an alternative classifier. Other than having different sets of input features, all aspects of the two classifiers were kept the same for fair comparisons. Table 3 .
Furthermore, we trained a distant supervised classification model for metastatic recurrence using these distantly labeled patients (1,302 as MBC and 7,590 not enough evidence of MBC) using a combination of CCR and NLP-derived features. A summary of all CCR features used in our classifier is listed in Table 1 . Regularization parameter lambda was chosen to be 0.0451.
Using 10-fold cross validation within the training data, we obtained the highest F-1 score of 0.89 with a probability cut-off of 0.4. This cut-off was applied to be evaluated using the 146 manually annotated records in the gold-standard set. Our final classifier achieved an area under the receiver operating characteristic curve (AUC) of 0.925, with 95% confidence interval 0.880-0.969 (DeLong) (Figure 2) (25) . There were 9 false-positives and 10 false-negatives, corresponding to sensitivity=0.861, specificity=0.878 and overall accuracy=0.870 ( from text processing step and 72 reviewed by physicians). This result is consistent with a recent report from the SEER registry using unrelated methods (6) . Table 4 
Discussion
The lack of high-quality longitudinal databases that can be used to study metastatic recurrence is the biggest obstacle to practice-based evidence on how patients die from cancer. To address this problem, we developed a novel scalable framework that enables retrospective MBC case detection with good performance. The contribution of this work is three-fold. First, we retrieved information from the unstructured text of clinical notes by developing a custom NLP extraction tool for metastatic recurrence. Second, we applied a semi-supervised machine learning technique, distant supervision, to the problem of metastatic recurrence classification.
Lastly, we leveraged complementary data sources, specifically medical records from Stanford Health Care and the California Cancer Registry to develop a framework for detection of metastatic recurrence that can enable population-based studies of patients with metastatic cancer.
Our classification model for recurrent MBC achieved good discriminating power and was based on a combination of features from both the CCR and EMRs. For each data source, the top predictors appear in Supplementary Table S3 , by the relative rank of their model coefficient.
While many of the strongest predictors from the CCR were known risk factors for metastatic recurrence (i.e., more advanced stage, triple negative disease, earlier year of diagnosis), one of the strongest classifying feature for distant recurrence was being uninsured. We found that patient insurance characteristics were essential for optimal classification of patients with metastatic disease, underscoring the importance of a diverse set of predictors and emphasizing the influence of healthcare access on cancer outcomes.
Our work suggests that an important next step is to develop tools for temporal information extraction. Due to the relatively short time between metastatic recurrence and death, NLP approaches must perform at high accuracy to support meaningful survival analysis. Although we initially planned to estimate onset time for metastatic recurrence cases, we found that simple methods (e.g., using the timestamp of a note with a positive-affirmative MBC mention)
were not sufficient. Analyses of notes from ten patients found that the most common errors of this naïve approach were attributable to phrases such as "patient was diagnosed with Other limitations of this study include incomplete data due to patients receiving care outside of SHC; this is mitigated to some extent by statewide capture of treatment summaries by CCR but does not capture events outside of the state. Moreover, CCR is limited in treatment detail.
Lastly, our work has primarily focused on NLP-derived features from unstructured free-text data in the EMR and structured data from the CCR. The integration of structured data from the EMR, such as diagnoses, drugs and procedures that patients received as part of their treatment and continued survivorship care, may also improve classification, especially when there is ambiguity in describing metastasis in the notes or for patients without any clinical notes (12) .
Also, we used a relatively simple machine learning classifier: a generalized linear model. Use of decision tree analysis and more nuanced machine learning methods may improve classification performance.
In conclusion, we developed an open-source, machine learning MBC case detection framework that accurately labels breast cancer patients as metastatic or not using linked EMR-CCR data.
Our final classifier for constructing MBC cohorts leveraged both EMR and SEER data and outperformed one that uses CCR features only. As more linked datasets are developed (for example, the American Society of Clinical Oncology's CancerLinQ initiative 2 ), tools such as ours can readily be adapted for them. This approach has tremendous potential to identify cohorts of metastatic cancer patients and offer insights into the characteristics, care and outcomes of this important and understudied patient population. 
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